Are first ventilatory threshold and 6-minute walk test heart rate interchangeable? A pilot study in healthy elderlies and cardiac patients

Morard, Martin; Bosquet, Laurent; Laroche, Davy; Joussain, Charles; Besson, D.; Deley, Gaëlle; Casillas, Jean-Marie; Grémeaux, Vincent

doi:10.1016/j.rehab.2014.07.001

Cited by 7 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary outcome was cardiac function, measured by the left ventricular end diastolic diameter (LVDD), [ 27 ] left ventricular ejection fraction (LVEF), [ 28 ] cardiac output (CO), [ 29 ] every cardiac output (ECO), [ 30 ] and cardiac index (CI) [ 31 ] through the color Doppler echocardiography. The secondary outcomes included motor function, measured by the standard 6-MinuteWalk Test (6MWT), [ 32 ] and AEs related to the treatment of SQLXF. All the outcomes were measured before and after 6-month treatment.…”

Section: Methodsmentioning

confidence: 99%

A retrospective study of traditional Chinese medicine as an adjunctive therapy for patients with chronic heart failure

Sui

Liu²,

Tian³

et al. 2018

Medicine

View full text Add to dashboard Cite

This study retrospectively evaluated the effectiveness and safety of traditional Chinese medicine Shenqilixin Formula (SQLXF) as an adjunctive intervention for treating patients with chronic heart failure (CHF).This retrospective study included 135 patients with CHF. They were allocated to a treatment group or a control group according to the different treatments they received. Seventy five patients in the treatment group underwent SQLXF plus routine treatment, while 60 subjects in the control group received routine treatment only. The primary outcome was cardiac function. It was measured by the left ventricular end diastolic diameter (LVDD), left ventricular ejection fraction (LVEF), cardiac output (CO), every cardiac output (ECO), and cardiac index (CI). The secondary outcome included motor function. It was measured by the standard 6-MinuteWalk Test (6MWT). In addition, adverse events (AEs) were also recorded.Compared to subjects in the control group, patients in the treatment group revealed greater effectiveness in cardiac function, measured by LVEF (P < .05), CO (P < .05), and ECO (P < .05), and motor function, measured by the 6MWT scale (P < .05). Moreover, no significant differences of AEs were found between the 2 groups.SQLXF as an adjunctive therapy to routine treatment may help to improve both cardiac and motor function in patients with CHF.

show abstract

Section: Methodsmentioning

confidence: 99%

A retrospective study of traditional Chinese medicine as an adjunctive therapy for patients with chronic heart failure

Sui

Liu²,

Tian³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Control group deconditioning was in play. After rehabilitation, Morard et al [ 37 ] reported similar results in patients with coronary disease but not in a healthy elderly population or in chronic heart-failure patients, as also shown by Kervio et al [ 38 ]. Any useful role played by APA intensity in breast cancer patients remains debatable.…”

Section: Discussionmentioning

confidence: 58%

Can the Six-Minute Walk Test Be Used to Individualize Physical Activity Intensity in Patients with Breast Cancer?

Tubiana-Mathieu

Cornette

Mandigout

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Adapted physical activity (APA) aids breast cancer patients. It is necessary to use an adapted target heart rate (HR) when prescribing exercise intensity. Methods: In total, 138 patients previously included in two published randomized clinical trials underwent the CPET and 6MWT before and after adjuvant therapy. Of these patients, 85 had performed APA, and 53 had received only the usual therapy. HRs were recorded during the two tests. Results: Before starting chemotherapy, good agreement (intraclass correlation (ICC) 0.69; confidence interval at 95% IC0.95 (0.591–0.769); p < 0.001) and a moderate correlation were evident between the 6MWT-HR and ventilatory threshold HR of the CPET (r = 0.70; p < 0.001). Good agreement and a high positive correlation were noted only in the group who engaged in APA (ICC 0.77; IC0.95 (0.659–0.848); p < 0.001; r = 0.8; p < 0.01); moderate agreement and a moderate positive correlation were apparent in the control group (ICC 0.57; IC0.95 (0.329–0.74); p < 0.001; r = 0.6; p < 0.01). The correlations were independent of age and body mass index. Conclusions: The 6MWT-HR can be used to prescribe exercise intensity for breast cancer patients both before and after specific treatment with concomitant APA.

show abstract

“…Our results agree and reinforce existent literature. Morard et al (2015) reported agreement between HR VT1 in a symptom-limited incremental CPET on a cycle ergometer and HR 6MWT in CAD patients with an acceptable 95% confidence interval of bias from Bland–Altman analysis (−12.3 to 8.1 bpm). Similarly, in patients with chronic heart failure, Oliveira et al (2016) showed a high correlation between HR VT1 and HR 6MWT ( r =0.81; P <0.0001), with an acceptable SEE of 6.05 bpm.…”

Section: Discussionmentioning

confidence: 79%

“…During the 6MWT, all patients used the HR monitor (Polar S810i, Polar Electro Oy, Kempele, Finland) that continuously showed the HR throughout the 6-min test. The highest value of the HR was noted during the last 30 sec of the 6MWT (HR 6MWT ) ( Morard et al, 2015 ). Resting HR was assessed while the patients were standing for 60 sec, after a 5-min rest sitting.…”

Section: Methodsmentioning

confidence: 99%

Agreement between heart rate at first ventilatory threshold on treadmill and at 6-min walk test in coronary artery disease patients on β-blockers treatment

et al. 2021

View full text Add to dashboard Cite

The purpose of this study was to verify the accuracy of the agreement between heart rate at the first ventilatory threshold (HRVT1) and heart rate at the end of the 6-min walk test (HR6MWT) in coronary artery disease (CAD) patients on β-blockers treatment. This was a cross-sectional study with stable CAD patients, which performed a cardiopulmonary exercise test (CPET) on a treadmill and a 6-min walk test (6MWT) on nonconsecutive days. The accuracy of agreement between HRVT1 and HR6MWT was evaluated by Bland–Altman analysis and Lin’s concordance correlation coefficient (rc), mean absolute percentage error (MAPE), and standard error of estimate (SEE). Seventeen stable CAD patients on β-blockers treatment (male, 64.7%; age, 61± 10 years) were included in data analysis. The Bland–Altman analysis revealed a negative bias of -0.41 ± 6.4 bpm (95% limits of agreements, -13 to 12.2 bpm) between HRVT1 and HR6MWT. There was acceptable agreement between HRVT1 and HR6MWT (rc = 0.84; 95% confidence interval, 0.63 to 0.93; study power analysis= 0.79). The MAPE of the HR6MWT was 5.1% and SEE was 6.6 bpm. The ratio HRVT1/HRpeak and HR6MWT/HRpeak from CPET were not significantly different (81%± 5% vs. 81%± 6%, P= 0.85); respectively. There was a high correlation between HRVT1 and HR6MWT (r= 0.85, P< 0.0001). Finally, the results of the present study demonstrate that there was an acceptable agreement between HRVT1 and HR6MWT in CAD patients on β-blockers treatment and suggest that HR6MWT may be useful to prescribe and control aerobic exercise intensity in cardiac rehabilitation programs.

show abstract

Are first ventilatory threshold and 6-minute walk test heart rate interchangeable? A pilot study in healthy elderlies and cardiac patients

Cited by 7 publications

References 48 publications

A retrospective study of traditional Chinese medicine as an adjunctive therapy for patients with chronic heart failure

A retrospective study of traditional Chinese medicine as an adjunctive therapy for patients with chronic heart failure

Can the Six-Minute Walk Test Be Used to Individualize Physical Activity Intensity in Patients with Breast Cancer?

Agreement between heart rate at first ventilatory threshold on treadmill and at 6-min walk test in coronary artery disease patients on β-blockers treatment

Contact Info

Product

Resources

About